Markets Maxim ups Indaptus Therapeutics to buy from hold; PT $16 Maxim Group upgraded Indaptus Therapeutics (NASDAQ:INDP) to a “buy” rating from “hold” with a price target of $16, based on the potential of lead oncology program Decoy20 in pancreatic, liver and colorectal cancers as... October 19, 2021